Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Toward the molecular dissection of peritoneal pseudomyxoma.
· Ann Oncol · 2016 · PMID 27502722 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.
· Oncotarget · 2016 · PMID 27304188 · validated civic_curation pubmed
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
· J Clin Oncol · 2015 · PMID 25847936 · validated civic_curation pubmed
Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.
· BMC Cancer · 2015 · PMID 26674738 · validated civic_curation pubmed
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
· JAMA · 2010 · PMID 21177507 · validated civic_curation pubmed
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation

Showing 101–125 of 384 publications

← Previous
1
…
4
5
6
…
16
Next →

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

· Lancet Oncol · 2015 · PMID 26051236 · validated civic_curation pubmed

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

· Ann Oncol · 2015 · PMID 25899785 · validated civic_curation pubmed

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

· J Transl Med · 2016 · PMID 27154293 · validated civic_curation pubmed

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

· Breast Cancer Res Treat · 2011 · PMID 21594665 · validated civic_curation pubmed

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

· Cancer · 2012 · PMID 21882184 · validated civic_curation pubmed

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

· J Clin Oncol · 2012 · PMID 22370314 · validated civic_curation pubmed

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

· Proc Natl Acad Sci U S A · 2004 · PMID 15329413 · validated civic_curation pubmed

MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

· Clin Cancer Res · 2015 · PMID 25351745 · validated civic_curation pubmed

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.

· J Clin Oncol · 2011 · PMID 21969500 · validated civic_curation pubmed

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.

· Lancet Oncol · 2016 · PMID 27825636 · validated civic_curation pubmed

Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.

· Hum Pathol · 2015 · PMID 25628030 · validated civic_curation pubmed

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.

· J Clin Oncol · 2016 · PMID 27022112 · validated civic_curation pubmed

NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.

· Cancer · 2016 · PMID 26784937 · validated civic_curation pubmed

ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.

· Oncogene · 2014 · PMID 24037524 · validated civic_curation pubmed

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

· Clin Cancer Res · 2016 · PMID 26920887 · validated civic_curation pubmed

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed

Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

· Am J Pathol · 2001 · PMID 11438465 · validated civic_curation pubmed

Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization.

· Am J Surg Pathol · 2012 · PMID 22895266 · validated civic_curation pubmed